Enhanced effect of mutant granulocyte-colony-stimulating factor (KW-2228) on the growth of normal and leukemic hemopoietic progenitor cells in comparison with recombinant human granulocyte-colony-stimulating factor (G-CSF)

Acta Haematol. 1992;87(4):181-9. doi: 10.1159/000204756.

Abstract

We tested the in vitro effect of a novel granulocyte colony-stimulating factor (G-CSF) derivative (KW-2228) on the growth of G-CSF-dependent hemopoietic progenitor cells: granulocyte precursor cells (CFU-G), leukemic blast progenitors freshly obtained from 9 patients with acute myeloblastic leukemia (AML) and cells of a G-CSF-dependent human AML cell line (OCI/AML 1a). KW-2228 showed a higher stimulating effect than recombinant human G-CSF (rhCSF) on CFU-G; 3 out of 9 leukemic blast progenitors and OCI/AML 1a cells. The difference in biochemical stability between rhG-CSF and KW-2228 was considered to explain the superior colony-stimulating activity of KW-2228. The results show that KW-2228 will be a new granulopoietic factor.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Bone Marrow Cells
  • Cell Line
  • Cells, Cultured / cytology
  • Cells, Cultured / drug effects
  • Dose-Response Relationship, Drug
  • Granulocyte Colony-Stimulating Factor / pharmacology*
  • Hematopoietic Stem Cells / cytology
  • Hematopoietic Stem Cells / drug effects*
  • Humans
  • Leukemia, Myeloid, Acute / pathology*
  • Molecular Sequence Data
  • Recombinant Proteins / pharmacology
  • Stimulation, Chemical
  • Structure-Activity Relationship
  • Time Factors
  • Tumor Cells, Cultured / cytology
  • Tumor Cells, Cultured / drug effects

Substances

  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • nartograstim